Amgen and it’s subsidiary Onyx Pharmaceuticals Inc., have announced that the European Medicines Agency (EMA) has accepted their application for the marketing authorization of Kyprolis® (carfilzomib) as a treatment for relapsed myeloma patients who have received at least one previous line of treatment. The application, based on data from the Phase III ASPIRE trial comparing Kyprolis in combination with Revlimid and dexamethasone versus Revlimid and dexamethasone, has been granted accelerated assessment by the EMA.

 

Read full article